Ipamorelin

Overview

Ipamorelin is a selective growth hormone secretagogue that stimulates GH release by activating the ghrelin receptor (GHS-R1a). It is often favored over older GHRPs because clinical research (published in the European Journal of Endocrinology) found it produces dose-dependent GH release with little or no effect on ACTH and cortisol, giving it a comparatively clean side-effect profile among GHRPs. It is frequently stacked with CJC-1295 for a synergistic GH pulse, although controlled human outcome data specifically on the combination remains limited. It is not FDA-approved for human use and is prohibited in sport.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Stimulating GH/IGF-1 for fat loss and lean-mass support — marketed claim
• Recovery and sleep quality — marketed claim, limited controlled human outcome data
• Often combined with CJC-1295 ('CJC/Ipa') — marketed stack

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Labs — IGF-1 at baseline and follow-up; fasting glucose / HbA1c
• Body composition — InBody body-fat % and lean mass
• Whoop — slow-wave sleep and recovery trends
• Subjective — sleep quality, appetite (ghrelin pathway may influence hunger), recovery

Sources & References

1. [1]Raun et al. — Ipamorelin, the first selective growth hormone secretagogue (European Journal of Endocrinology)
2. [2]Ipamorelin evidence-based guide (2026) — Chia Health
3. [3]WADA Prohibited List — official (growth hormone secretagogues)